Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study-MedSci.cn

Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study

Desai, J; Markman, B; Friedlander, M; Gan, H; Horvath, L; Townsend, A; Millward, M; Jameson, M; Yen, CJ; Hou, MM; Hou, J; Wu, J; Liang, L; Deva, S

CANCER RESEARCH, 2019; 79 (13):

科室
- - 订阅+
  - 更多科室
工具
服务